Regulatory considerations for developing remote measurement technologies for Alzheimer's disease research.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 39232033.
- Also identified by DOI 10.1038/s41746-024-01211-8 and PMC identifier 11375004.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Remote Assessment of Disease and Relapse – Alzheimer’s Disease (RADAR-AD) consortium evaluated remote measurement technologies (RMTs) for assessing functional status in AD. The consortium engaged with the European Medicines Agency (EMA) to obtain feedback on identification of meaningful functional domains, selection of RMTs and clinical study design to assess the feasibility of using RMTs in AD clinical studies. We summarized the feedback and the lessons learned to guide future projects.